Objective:

To enhance gastroesophageal cancer care for patients who do not respond to standard treatment through novel therapies.

Key Findings:

• Gastrointestinal cancer accounts for about 33% of all cancer-related deaths globally.
• 70% of gastroesophageal cancer patients do not respond to standard treatment.
• Chromosomal instability in patients leads to poorer responses to immune checkpoint inhibitors.

Interpretation:

The grant aims to leverage larger data sets and biomarker data to drive innovative studies and clinical trials in gastroesophageal cancer.

Limitations:

• The study's findings may be limited by the specific patient population and tumor characteristics.
• The effectiveness of new therapies remains to be validated in clinical trials.

Conclusion:

The collaboration and funding from SU2C represent a significant step towards developing effective therapies for gastroesophageal cancer patients who currently have limited treatment options.